These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 26244026)

  • 1. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management.
    O'Driscoll T; Crank CW
    Infect Drug Resist; 2015; 8():217-30. PubMed ID: 26244026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combatting resistant enterococcal infections: a pharmacotherapy review.
    Mercuro NJ; Davis SL; Zervos MJ; Herc ES
    Expert Opin Pharmacother; 2018 Jun; 19(9):979-992. PubMed ID: 29877755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing therapy for vancomycin-resistant enterococci (VRE).
    Linden PK
    Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
    J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.
    Johnson JA; Feeney ER; Kubiak DW; Corey GR
    Open Forum Infect Dis; 2015 Dec; 2(4):ofv156. PubMed ID: 26677455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence.
    Yim J; Smith JR; Rybak MJ
    Pharmacotherapy; 2017 May; 37(5):579-592. PubMed ID: 28273381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antimicrobial agents as therapy for resistant gram-positive cocci.
    Lentino JR; Narita M; Yu VL
    Eur J Clin Microbiol Infect Dis; 2008 Jan; 27(1):3-15. PubMed ID: 17899228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic options for vancomycin-resistant enterococcal bacteremia.
    Barber KE; King ST; Stover KR; Pogue JM
    Expert Rev Anti Infect Ther; 2015 Mar; 13(3):363-77. PubMed ID: 25661903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children.
    Tamma PD; Hsu AJ
    Curr Opin Infect Dis; 2014 Dec; 27(6):517-27. PubMed ID: 25313503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
    Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
    J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Epidemiology of Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Clinical Specimens in the Northwest of Iran.
    Jahansepas A; Ahangarzadeh Rezaee M; Hasani A; Sharifi Y; Rahnamaye Farzami M; Dolatyar A; Aghazadeh M
    Microb Drug Resist; 2018 Oct; 24(8):1165-1173. PubMed ID: 29708837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence and management of drug-resistant enterococcal infections.
    Arias CA; Murray BE
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):637-55. PubMed ID: 18847403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin-resistant enterococcal bacteremia pharmacotherapy.
    Patel R; Gallagher JC
    Ann Pharmacother; 2015 Jan; 49(1):69-85. PubMed ID: 25352037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections.
    Kauffman CA
    J Antimicrob Chemother; 2003 Jun; 51 Suppl 3():iii23-30. PubMed ID: 12801939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
    Chou YY; Lin TY; Lin JC; Wang NC; Peng MY; Chang FY
    J Microbiol Immunol Infect; 2008 Apr; 41(2):124-9. PubMed ID: 18473099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.